Clinical Trial Update: A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A biomarker-directed Phase 2 trial of tamibarotene (SY-1425) in acute myeloid leukemia and myelodysplastic syndrome has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Tamibarotene (tamibarotene)

Snippet

Sponsor: Syros Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-12-13